Acutus Medical Inc. (AFIB): Price and Financial Metrics

Acutus Medical Inc. (AFIB): $16.61

-0.06 (-0.36%)

POWR Rating

Component Grades














  • Growth is the dimension where AFIB ranks best; there it ranks ahead of 38.75% of US stocks.
  • The strongest trend for AFIB is in Quality, which has been heading down over the past 31 weeks.
  • AFIB ranks lowest in Sentiment; there it ranks in the 2nd percentile.

AFIB Stock Summary

  • AFIB's went public 0.84 years ago, making it older than only 0.05% of listed US stocks we're tracking.
  • AFIB's price/sales ratio is 44.1; that's higher than the P/S ratio of 94.11% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AFIB comes in at -36.18% -- higher than that of only 7.02% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acutus Medical Inc are BIOL, KALA, DUO, OTRK, and VIVE.
  • AFIB's SEC filings can be seen here. And to visit Acutus Medical Inc's official web site, go to

AFIB Price Target

For more insight on analysts targets of AFIB, see our AFIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.8 (Moderate Buy)

AFIB Stock Price Chart Interactive Chart >

Price chart for AFIB

AFIB Price/Volume Stats

Current price $16.61 52-week high $38.99
Prev. close $16.67 52-week low $11.18
Day low $16.31 Volume 279,000
Day high $16.97 Avg. volume 325,228
50-day MA $14.07 Dividend yield N/A
200-day MA $23.11 Market Cap 467.14M

Acutus Medical Inc. (AFIB) Company Bio

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.

AFIB Latest News Stream

Event/Time News Detail
Loading, please wait...

AFIB Latest Social Stream

Loading social stream, please wait...

View Full AFIB Social Stream

Latest AFIB News From Around the Web

Below are the latest news stories about Acutus Medical Inc that investors may wish to consider to help them evaluate AFIB as an investment opportunity.

Acutus Medical to Present at the 41st Annual William Blair Growth Stock Conference

CARLSBAD, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the 41st Annual William Blair Growth Stock Conference on Thursday, June 3, 2021 at 12:20 p.m. Eastern Time. A live webcast of the presentation may be accessed by visiting A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 30 days following the presentation. About Acutus MedicalAcutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is c...

Yahoo | May 20, 2021

Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q1 2021 Results - Earnings Call Transcript

Acutus Medical, Inc. (AFIB) Q1 2021 Earnings Conference Call May 12, 2021, 04:30 PM ET Company Participants Caroline Corner - Investor Relations Vince Burgess - President and Chief Executive Officer David Roman - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Margaret Kaczor - William Blair Bill Plovanic...

SA Transcripts on Seeking Alpha | May 13, 2021

Acutus Medical EPS misses by $0.04, beats on revenue

Acutus Medical (AFIB): Q1 Non-GAAP EPS of -$0.97 misses by $0.04; GAAP EPS of -$1.04 misses by $0.07.Revenue of $3.59M (+127.2% Y/Y) beats by $0.81M.Press Release...

Seeking Alpha | May 12, 2021

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Ap...

Benzinga | May 12, 2021

Acutus Medical Announces CE Mark Approval for Suite of Next Generation EP Products in Europe

Expanded and Product Portfolio Strengthens Offering in Access and Therapy Guidance AcQCross Transseptal Crossing Device Versatility to be utilized with top sheaths currently used in left atrium electrophysiology and structural heart procedures. Second Generation AcQGuide MAX Sheath These sheathes provide improved handling and deliverability to facilitate faster anatomy reconstruction. AcQMap Next Generation Mapping Catheter Integrated high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling, and maneuverability. CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announce...

Yahoo | May 12, 2021

Read More 'AFIB' Stories Here

AFIB Price Returns

1-mo 21.68%
3-mo -7.72%
6-mo -44.80%
1-year N/A
3-year N/A
5-year N/A
YTD -42.35%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.775 seconds.